In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men. PrCa is marked by uncontrolled cellular growth that leads to abnormal enlargement of the prostate gland. The metastatic ...

The pharma giant hosted its ninth annual Blue Jacket Fashion Show in collaboration with designer Frederick Anderson in New ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...

Announcing a new publication for Acta Materia Medica journal. Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men.

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, and SBRT in metastatic castration-sensitive prostate cancer.

On Feb. 1, Novartis Pharmaceuticals Canada Inc. announced that the Nova Scotia government is funding Pluvicto injections for ...

Hormonal therapy, namely targeting androgen ... PSMA is a very promising target, but there are other targets that are being developed in advanced prostate cancer.

An innovative new prostate cancer treatment is now available at the North Coast Cancer Institute in Lismore, offering significant reductions in ...

More Than 20 Alpha Therapies Are In Clinical Trials Says KUICK RESEARCH In Recent PublicationDelhi, Jan. 29, 2025 (GLOBE ...